Skip to main content
Contact Us
Subscribe
E-Edition
86°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pacira Pharm Inc
(NQ:
PCRX
)
20.21
+0.84 (+4.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pacira Pharm Inc
< Previous
1
2
3
4
Next >
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
July 17, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
Top 5 Health Care Stocks That May Explode In July
July 08, 2024
Via
Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
July 03, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
July 02, 2024
Via
Benzinga
NASDAQ:PCRX: good value for what you're paying.
June 26, 2024
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals.
Via
Chartmill
NASDAQ:PCRX, an undervalued stock with good fundamentals.
June 05, 2024
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued.
Via
Chartmill
Analyst Ratings For Pacira BioSciences
May 08, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
April 09, 2024
Via
Benzinga
Navigating 4 Analyst Ratings For Pacira BioSciences
March 01, 2024
Via
Benzinga
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
May 15, 2024
When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024
May 07, 2024
PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
March 28, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
March 01, 2024
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Preview: Pacira BioSciences's Earnings
February 28, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
NASDAQ:PCRX is an undervalued gem with solid fundamentals.
January 19, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals.
Via
Chartmill
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
December 20, 2023
Via
Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 09, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
December 20, 2023
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.
Via
Chartmill
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
November 29, 2023
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued.
Via
Chartmill
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
November 08, 2023
Investors should take notice ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
Earnings Preview: Pacira BioSciences
November 01, 2023
Via
Benzinga
Analyst Expectations for Pacira BioSciences's Future
October 23, 2023
Via
Benzinga
4 Analysts Have This to Say About Pacira BioSciences
August 03, 2023
Via
Benzinga
Analyst Ratings for Pacira BioSciences
July 13, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
September 11, 2023
Monday's session saw 175 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
August 03, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 08, 2023
Friday's session saw 225 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.